In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
19 authors at 4 institutions in 2 countries.
Derek TshiabuilaCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0001-5221-2126 Wonderful ChogaCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0001-7606-0569 San E JamesCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-5736-664X Tongai MapongaDivision of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa & National Health Laboratory Service.ORCID 0000-0002-6876-3712 Wolfgang PreiserDivision of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa & National Health Laboratory Service.ORCID 0000-0002-0254-7910 Gert van ZylDivision of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa & National Health Laboratory Service.ORCID 0000-0003-3021-5101 Monika MoirCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0003-1095-1910 Stephanie van WykCollaborating Centre for Optimizing Antimalarial Therapy (CCOAT), Mitigating Antimalarial Resistance Consortium in South East Africa (MARC SEA), Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, South Africa.ORCID 0000-0002-2655-8518 Jennifer GiandhariKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban, South Africa.ORCID 0000-0002-2944-4583 Sureshnee PillayKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban, South Africa.ORCID 0000-0001-9288-7996 Ugochukwu J AnyanejiKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban, South Africa.
Richard J LessellsKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban, South Africa.ORCID 0000-0003-0926-710X Yeshnee NaidooCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-9040-963X Tomasz Janusz SankoCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-4154-7067 Eduan WilkinsonCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-2503-9441 Houriiyah TegallyCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.
Cheryl BaxterCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-6033-7655 Darren P MartinComputational Biology Division, Department of Integrative Biomedical Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa.ORCID 0000-0002-8785-0870 Tulio de OliveiraCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, South Africa.ORCID 0000-0002-3027-5254 Stellenbosch University · ZAUniversity of KwaZulu-Natal · ZANational Health Laboratory Service · ZAUniversity of Cape Town · ZA
Funding
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MRole of Data Streams In Informing Infection Dynamics in Africa- INFORM AfricaU54TW012041 · FIC · INSTITUTE OF HUMAN VIROLOGY · PI Alash'le G. Abimiku, Tulio de Paiva Nazareth Andrade De Oliveira · 2021 to 2026
$6.9MFIC NIH HHS U54 TW012041NIAID NIH HHS U01 AI151698
6 · The paper itselfAbstract
Chronic hepatitis B virus (HBV) infection remains a significant public health concern, particularly in Africa, where there is a substantial burden. HBV is an enveloped virus, with isolates being classified into ten phylogenetically distinct genotypes (A - J) determined based on full-genome sequence data or reverse hybridization-based diagnostic tests. In practice, limitations are noted in that diagnostic sequencing, generally using Sanger sequencing, tends to focus only on the S-gene, yielding little or no information on intra-patient HBV genetic diversity with very low-frequency variants and reverse hybridization detects only known genotype-specific mutations. To resolve these limitations, we developed an Oxford Nanopore Technology (ONT)-based HBV genotyping protocol suitable for clinical virology, yielding complete HBV genome sequences and extensive data on intra-patient HBV diversity. Specifically, the protocol involves tiling-based PCR amplification of HBV sequences, library preparation using the ONT Rapid Barcoding Kit, ONT GridION sequencing, genotyping using Genome Detective software, recombination analysis using jpHMM and RDP5 software, and drug resistance profiling using Geno2pheno software. We prove the utility of our protocol by efficiently generating and characterizing high-quality near full-length HBV genomes from 148 left-over diagnostic Hepatitis B patient samples obtained in the Western Cape province of South Africa, providing valuable insights into the genetic diversity and epidemiology of HBV in this region of the world.
Indexed as
HBVNGSONTRecombinationWhole-genome sequencing
Identifiers
PMID38293032
PMCPMC10827254
OpenAlexW4391046946
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390